Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">CholestaGel non-absorbable hydrogel: GELX began a Phase IIb dose-ranging trial</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

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

(Ono terminates CholestaGel rights in Japan, B3.) ......

CholestaGel non-absorbable hydrogel: GELX began a Phase IIb dose-ranging trial

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Discovery & Translation Analysis

Discovery & Translation

Hot Topics

BioCentury Podcasts 

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data Coverage

BCIQ Data

All Events

At the East-West Summit, you will meet key players looking to globalize innovation from across Asia.

East-West Biopharma Summit 2026

Bio€quity Europe

Grand Rounds — U.S.

Grand Rounds — Europe

China Healthcare Summit Inquiry

Podcast: The BioCentury Show

Podcast: BioCentury This Week

Webinars

Events

My Workspace

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Request a Subscription

Sponsorship & Branding Inquiry

Media Kit

Request BioCentury's BCIQ Brochure

Customer Resource Center

Career Opportunities

Request a Trial

Contact

Home